RBC Capital maintained an Outperform rating on Celgene (NASDAQ: CELG) with a price target of $150. Earlier shares of Celgene ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE